Press release
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress, being held April 3-5, 2025, in Athens, Greece. The posters demonstrate the ability of the DecisionDx-Melanoma test to guide more informed, risk-aligned management decisions through the precise risk-stratification of patients with melanoma. \"The findings being presented at EADO demonstrate that DecisionDx-Melanoma provides valuable biological insights that complement traditional staging and may help clinicians tailor surveillance and treatment plans based on a patient's individual predicted risk of metastasis,” said Brent Moody, M.D., dermatologist and Mohs micrographic surgeon at Heritage Medical Associates in Nashville, Tennessee. “By better identifying which patients may benefit from intensified monitoring and adjuvant therapy, the test has the potential to significantly improve melanoma outcomes through more personalized care directed to those who need it most.\" Castle will present the following posters at EADO. The corresponding abstracts can be found in the digital Book of Abstracts available for download on the EADO website. DecisionDx-Melanoma Poster P5-30: Improved prognostic guidance with 31-gene expression profiling for patients with stage IIB-IIC cutaneous melanoma: a SEER collaborationAbstract: A-314Lead Author: Brent Moody, M.D., Heritage Medical AssociatesKey takeaways: In the study, DecisionDx-Melanoma effectively stratified melanoma-specific survival and overall survival in a real-world population of clinically tested patients with stage IIb-IIC CM (p","length":3097,"tagName":"div"}]